UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 290

Sortiert nach

T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status

American journal of neuroradiology : AJNR, 2015-12, Vol.36 (12), p.2256-2261

2015

Volltextzugriff (PDF)

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

Cancer cell, 2004-11, Vol.6 (5), p.517-527

2004

Volltextzugriff (PDF)

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

The New England journal of medicine, 2005-11, Vol.353 (19), p.2012-2024

2005

Volltextzugriff (PDF)

Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR

Proceedings of the National Academy of Sciences - PNAS, 2001-08, Vol.98 (18), p.10314-10319

2001

Volltextzugriff (PDF)

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression

The Journal of biological chemistry, 2004-01, Vol.279 (4), p.2737-2746

2004

Volltextzugriff (PDF)

A.6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2)

Canadian journal of neurological sciences, 2024-06, Vol.51 (s1), p.S4-S4

2024

Volltextzugriff (PDF)

Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts

Cancer research (Chicago, Ill.), 2002-09, Vol.62 (18), p.5254-5259

2002

Volltextzugriff (PDF)

Treatment of Scedosporium apiospermum Brain Abscesses with Posaconazole

Clinical infectious diseases, 2002-06, Vol.34 (12), p.1648-1650

2002

Volltextzugriff (PDF)

Liquid biopsy in gliomas: A RANO review and proposals for clinical applications

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (6), p.855-871

2022

Volltextzugriff (PDF)

TORward AKTually useful mouse models

Nature medicine, 2004-06, Vol.10 (6), p.579-580

2004

Volltextzugriff (PDF)

Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Annals of oncology, 2016-10, Vol.27, p.vi106-vi106

2016

Volltextzugriff (PDF)

Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

Cancer cell, 2007-06, Vol.11 (6), p.555-569

2007

Volltextzugriff (PDF)

KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii4-ii5

2023

Volltextzugriff (PDF)

Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis

Cancer cell, 2009-07, Vol.16 (1), p.44-54

2009

Volltextzugriff (PDF)

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii2-iii2

2019

Volltextzugriff (PDF)

Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Annals of oncology, 2016-10, Vol.27, p.vi105-vi105

2016

Volltextzugriff (PDF)

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Nature medicine, 2006-01, Vol.12 (1), p.122-127

2006

Volltextzugriff (PDF)

Cocaine and Buerger disease: is there a pathogenetic association?

Archives of internal medicine (1960), 2000-07, Vol.160 (13), p.2057

2000

Volltextzugriff (PDF)

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

Neuro-oncology (Charlottesville, Va.), 2015-02, Vol.17 (2), p.180-188

2015

Volltextzugriff (PDF)

OS1.7 Genomic attributes of tumor evolution and treatment response in diffuse glioma

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii218-iii218

2018

Volltextzugriff (PDF)

Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency

Journal of general virology, 2010-02, Vol.91 (2), p.463-469

2010

Volltextzugriff (PDF)

PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii47-iii47

2014

Volltextzugriff (PDF)

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

The New England journal of medicine, 2006-02, Vol.354 (8), p.884-884

2006

Volltextzugriff (PDF)

A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3085-3085

2010

Volltextzugriff (PDF)

Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2065-2065

2010

Volltextzugriff (PDF)

1 – 25 von 290

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(258)
Mit Volltextzugriff
(234)

Publikationsform

Artikel
(269)
Buchkapitel
(19)
Bücher
(1)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(158)
Humans
(144)
Life Sciences & Biomedicine
(143)
Oncology
(79)
Mutation
(54)
Animals
(49)
Male
(40)
Tumors
(40)
Mice
(33)
Adult
(32)
Female
(32)
Cancer
(30)
Cell Line, Tumor
(24)
Aged
(23)
Brain Neoplasms - Genetics
(23)
Middle Aged
(23)
Science & Technology - Other Topics
(23)
Signal Transduction
(23)
Glioma - Genetics
(22)
Brain Cancer
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression

A.6 INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2)

Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts

Treatment of Scedosporium apiospermum Brain Abscesses with Posaconazole

Liquid biopsy in gliomas: A RANO review and proposals for clinical applications

TORward AKTually useful mouse models

Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Cocaine and Buerger disease: is there a pathogenetic association?

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

OS1.7 Genomic attributes of tumor evolution and treatment response in diffuse glioma

Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency

PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma

Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)

Suchergebnisse filtern